Vertaling van "belgian care " (Nederlands → Frans) :

de machtiging, volgens de modaliteiten in de huidige beraadslaging, aan de Belgian Heart Rhythm Association en de Belgian Working Group on Interventional Cardiology voor het ophalen van gecodeerde persoonsgegevens uit de gegevensbanken E-Care Qermid@Coronaire stents en E-Care QERMID@Pacemakers om statistieken op te stellen.
autorise, selon les modalités mentionnées dans la présente délibération, la Belgian Heart Rhythm Association et le Belgian Working Group on Interventional Cardiology à extraire les données à caractère personnel codées concernées des banques de données E-Care QERMID@Tuteurs coronaires et E-Care QERMID@Pacemakers en vue de la réalisation de statistiques.

The Resident Assessment Instrument (RAI) 444 is originally developed to Only for breast cancer and colon cancer, the US has higher survival rates assess the care needs of the elderly in institutions, and has later been than Belgium (data shown in documentation sheet in Supplement S1). To extended with instruments for different care settings and subgroups. In be able to distinguish the effect of early screening from the actual care, Belgium a national pilot project (the BelRAI) is ongoing, but is not yet implemented in all care settings: the assessment instruments for home care, relative survival rates should be compared across countries by stage, for long-term care facilities and acute care have already been adapted to information which is not yet available at international level. the Belgian situation (details in Appendix C).
Belgium a national pilot project (the BelRAI) is ongoing, but is not yet be able to distinguish the effect of early screening from the actual care, implemented in all care settings: the assessment instruments for home care, relative survival rates should be compared across countries by stage, for long-term care facilities and acute care have already been adapted to information which is not yet available at international level. the Belgian situation (details in Appendix C).

Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 185C (D/2012/10.273/61) Available from: [http ...]
Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 185C (D/2012/10.273/61) Available from: [http ...]

De definitie van de principes, de functionaliteiten en de architectuur van het verwijzingsrepertorium en van het project " hubs & metahub" gebeurt onder leiding van een begeleidingscomité, genaamd " Belgian Care Providers Telematic Advisory Group - G19" , die één van de werkgroepen van het Overlegcomité zal worden wanneer dit laatste effectief opgericht wordt.
La définition des principes, des fonctionnalités et de l’architecture du répertoire de références -et du projet « hubs & metahub »- est réalisée sous l’égide d’un comité d’accompagnement dénommé « Belgian Care Providers Telematic Advisory Group - G19 » qui deviendra un des groupes de travail du Comité de Concertation lors de la mise en place effective de ce dernier.

Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 191C (D/2012/10.273/88) Available from: [http ...]
Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 191C (D/2012/10.273/88) Available from: [http ...]

Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 189 (D/2012/10.273/76) Available from: [http ...]
Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 189 (D/2012/10.273/76) Available from: [http ...]

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

Brussels: Belgian Health Care Knowledge Centre (KCE); 2013. KCE Reports 200 (D/2013/10.273/15) Available from: [http ...]
Brussels: Belgian Health Care Knowledge Centre (KCE); 2013. KCE Reports 200 (D/2013/10.273/15) Available from:

Brussels: Belgian Health Care Knowledge Centre (KCE); 2011. KCE Reports 153C (D/2011/10.273/06) Available from: [http ...]
Brussels: Belgian Health Care Knowledge Centre (KCE); 2011. KCE Reports 153C (D/2011/10.273/06) Available from: [http ...]